See up to 3 months of RGNX. The 7-day demo opens the 1M and 3M ranges and puts RGNX on your watchlist.
Start 7-day demoLatest RGNX insider trades
About REGENXBIO Inc. (RGNX)
REGENXBIO Inc. is an SEC registrant, filing under CIK 0001590877, classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
RGNX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 102,603 | $949K |
| Grant or award | 2 | 85,041 | |
| Tax withholding / forfeiture | 4 | 17,303 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
RGNX insider transactions (Form 4)
5233 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Craig Malzahn - Officer | Tax withholding / forfeiture | Common Stock | 234 footnote F1 | $9.32 | $2K | |
| ||||||
| Mitchell Chan - Officer | Tax withholding / forfeiture | Common Stock | 4,902 footnote F1 | $9.32 | $46K | |
| ||||||
| Gregory Austin Ciongoli - Director | Grant or award | Common Stock | 15,432 footnote F1 | $0.00 | - | |
| Gregory Austin Ciongoli - Director | Open-market purchase | Common Stock | 49,196 | $9.14 footnote F2 | $450K | |
| Gregory Austin Ciongoli - Director | Open-market purchase | Common Stock | 53,407 | $9.36 footnote F3 | $500K | |
| Gregory Austin Ciongoli - Director | Grant or award | Stock Options (Right to buy) | 69,609 | $0.00 | - | |
| ||||||
| Steve Pakola - Officer | Tax withholding / forfeiture | Common Stock | 7,468 footnote F1 | $9.69 | $72K | |
| ||||||
| Patrick J. Christmas - Officer | Tax withholding / forfeiture | Common Stock | 4,699 footnote F1 | $9.69 | $46K | |
| ||||||
 Curran Simpson - Officer | Grant or award | Common Stock | 951 | $7.00 footnote F2 | $7K | |
| Curran Simpson - Officer | Grant or award | Common Stock | 1,453 | $10.18 footnote F4 | $15K | |
| Curran Simpson - Officer | Tax withholding / forfeiture | Common Stock | 6,818 footnote F5 | $13.09 | $89K | |
| ||||||
| Steve Pakola - Officer | Option exercise | Common Stock | 2,161 | $7.86 | $17K | |
| Steve Pakola - Officer | Open-market sale | Common Stock | 2,161 | $13.64 | $29K | |
| Steve Pakola - Officer | Option exercise | Stock Options (Right to Buy) | 2,161 | $0.00 | - | |
| Steve Pakola - Officer | Open-market sale | Common Stock | 19,608 | $11.04 footnote F2 | $216K | |
| Steve Pakola - Officer | Option exercise | Common Stock | 36,725 | $7.86 | $289K | |
| Steve Pakola - Officer | Open-market sale | Common Stock | 36,725 | $12.86 | $472K | |
| Steve Pakola - Officer | Option exercise | Stock Options (Right to Buy) | 36,725 | $0.00 | - | |
| ||||||
| Daniel Tasse | Grant or award | Common Stock | 9,807 footnote F1 | $0.00 | - | |
| Daniel Tasse | Grant or award | Stock Options (Right to Buy) | 46,600 | $0.00 | - | |
| ||||||
| David C. Stump | Grant or award | Common Stock | 9,807 footnote F1 | $0.00 | - | |
| David C. Stump | Grant or award | Stock Options (Right to Buy) | 46,600 | $0.00 | - | |
| ||||||
| Jennifer Zachary | Grant or award | Common Stock | 9,807 footnote F1 | $0.00 | - | |
| Jennifer Zachary | Grant or award | Stock Options (Right to Buy) | 46,600 | $0.00 | - | |
| ||||||
| Kenneth T. Mills | Grant or award | Common Stock | 9,807 footnote F1 | $0.00 | - | |
| Kenneth T. Mills | Grant or award | Stock Options (Right to Buy) | 46,600 | $0.00 | - | |
| ||||||
| George V. Migausky | Grant or award | Common Stock | 9,807 footnote F1 | $0.00 | - | |
| George V. Migausky | Grant or award | Stock Options (Right to Buy) | 46,600 | $0.00 | - | |
| ||||||
| Argeris N. Karabelas | Grant or award | Common Stock | 9,807 footnote F1 | $0.00 | - | |
| Argeris N. Karabelas | Grant or award | Stock Options (Right to Buy) | 46,600 | $0.00 | - | |
| ||||||
 Alexandra Glucksmann | Grant or award | Common Stock | 9,807 footnote F1 | $0.00 | - | |
| Alexandra Glucksmann | Grant or award | Stock Options (Right to Buy) | 46,600 | $0.00 | - | |
| ||||||
| Allan M. Fox | Grant or award | Common Stock | 9,807 footnote F1 | $0.00 | - | |
| Allan M. Fox | Grant or award | Stock Options (Right to Buy) | 46,600 | $0.00 | - | |
| ||||||
| Jean Bennett | Grant or award | Common Stock | 9,807 footnote F1 | $0.00 | - | |
| Jean Bennett | Grant or award | Stock Options (Right to Buy) | 46,600 | $0.00 | - | |
| ||||||
| Steve Pakola - Officer | Open-market sale | Common Stock | 15,309 | $11.02 footnote F2 | $169K | |
| ||||||
| Steve Pakola - Officer | Open-market sale | Common Stock | 5,124 | $10.35 | $53K | |
| Patrick J. Christmas - Officer | Tax withholding / forfeiture | Common Stock | 4,700 footnote F1 | $11.16 | $52K | |
| ||||||
| Steve Pakola - Officer | Tax withholding / forfeiture | Common Stock | 5,267 footnote F1 | $11.16 | $59K | |
| ||||||
| Kenneth T. Mills | Option exercise | Common Stock | 225,000 | $13.09 | $2.95M | |
| Kenneth T. Mills | Tax withholding / forfeiture | Common Stock | 221,753 | $13.41 | $2.97M | |
| Kenneth T. Mills | Option exercise | Stock Options (Right to Buy) | 225,000 | $0.00 | - | |
| Curran Simpson - Officer | Open-market sale | Common Stock | 20,811 | $12.62 footnote F2 | $263K | |
| ||||||
| Curran Simpson - Officer | Open-market sale | Common Stock | 7,624 | $10.03 | $76K | |
| Curran Simpson - Officer | Open-market sale | Common Stock | 7,734 | $10.02 | $77K | |
| Craig Malzahn - Officer | Tax withholding / forfeiture | Common Stock | 234 | $8.93 | $2K | |
| Mitchell Chan - Officer | Tax withholding / forfeiture | Common Stock | 4,901 | $8.93 | $44K | |
| Patrick J. Christmas - Officer | Tax withholding / forfeiture | Common Stock | 4,699 | $8.19 | $38K | |
| Curran Simpson - Officer | Tax withholding / forfeiture | Common Stock | 4,701 | $8.23 | $39K | |
| David C. Stump | Grant or award | Common Stock | 7,768 | $0.00 | - | |
| David C. Stump | Grant or award | Stock Options (Right to Buy) | 39,815 | $0.00 | - | |
Item 1.01
Item 5.02, 9.01
Item 7.01, 8.01, 9.01
Item 2.02, 9.01
Recent RGNX Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
RGNX insider trading FAQ
What is the latest insider trade for RGNX?
REGENXBIO Inc. (RGNX) had 5 insider filings in the last 90 days, with the most recent on 2026-09-03. The full record for RGNX runs to 33 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying RGNX stock?
2 insider purchases of RGNX were filed in the last 90 days, totaling $949K.
How many insiders are selling RGNX stock?
No insider sales of RGNX were filed in the last 90 days. 9 sales are on record for this company.
Where can I see RGNX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects RGNX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Craig Malzahn view on EDGAR
- - Mitchell Chan view on EDGAR
- - Gregory Austin Ciongoli view on EDGAR
- - Steve Pakola view on EDGAR
- - Patrick J. Christmas view on EDGAR
- - Curran Simpson view on EDGAR
- - Steve Pakola view on EDGAR
- - Steve Pakola view on EDGAR
- - Daniel Tasse view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where RGNX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow RGNX with a 7-day demo
- RGNX on your watchlist
- Every RGNX Form 4 filing on record
- Up to 3 months of RGNX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
